相关实验视频

Updated: May 5, 2026

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Published on: August 12, 2021

在COVID-19中SGLT2抑制剂:总体审查,元分析和贝叶斯敏感性评估

Vinay Suresh¹, Muhammad Aaqib Shamim², Victor Ghosh³

¹King George's Medical University, Lucknow 226003, India.

Diseases (Basel, Switzerland)

|March 26, 2025

概括

-葡萄糖携带载体-2 抑制剂 (SGLT2is) 显著降低了COVID-19患者2型糖尿病的死亡率和住院治疗. 对于住院后使用和危急情况需要进一步研究.

科学领域:

传染性疾病传染性疾病
内分泌学在内分泌学.
心脏病学心脏病学

背景情况:

越来越多的证据表明,抗糖尿病药物可能会降低COVID-19死亡率.
这项研究侧重于SGLT2抑制剂 (SGLT2is) 用于COVID-19患者的2型糖尿病 (T2DM).

研究的目的:

在COVID-19患有T2DM的患者中进行SGLT2抑制剂的总体审查和元分析.
评估SGLT2is在这个患者群体中的疗效和安全性.

主要方法:

在MEDLINE,EMBASE,Cochrane和ClinicalTrials.gov数据库中进行系统搜索.
系统性审查和元分析的总体综述,使用AMSTAR 2.0.0进行批判性评估.
对相关试验和观察性研究的元分析,遵循PRISMA指南.

主要成果:

在T2DM的COVID-19患者中,SGLT2显著降低了死亡率 (OR 0.67) 和住院 (OR 0.84) 的几率.
贝叶斯分析支持了大多数发现;然而,注意到了一些差异.
观察到糖尿病酸症的几率增加 (OR 1.20). 证据质量低至非常低.

结论:

预防性SGLT2i使用减少了COVID-19糖尿病患者的死亡率和住院治疗.
在住院后和在危急条件下SGLT2的有效性仍然不确定.
个性化患者评估对于将SGLT2is整合到COVID-19管理中至关重要.

关键词:

贝叶斯敏感性贝叶斯敏感性在 COVID-19 疫情中,SGLT2 抑制剂的使用.这就是SGLT2i.住院治疗住院治疗这是一个元分析.死亡率死亡率 2型糖尿病是什么?

更多相关视频

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

相关概念视频

Single Nucleotide Polymorphisms-SNPs

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...

Glucose Transporters

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...